Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

Highlights

• The EMPATICC trial found no significant difference in the primary hierarchical endpoint (days alive and able to wash, walking ability, and global assessment) between optimized heart failure (HF) therapy and placebo in patients with advanced cancer.
• The study population faced a high 30-day mortality rate of 32%, which significantly impacted the primary analysis.
• Among the 30-day survivors, HF therapy significantly reduced NT-proBNP levels by 41% and slightly improved left ventricular ejection fraction (LVEF).
• Subjective well-being, measured by the Patient Global Assessment (PGA), showed improvement in the treatment group among those who survived the initial 30-day phase.

Background: The Overlap of Cancer and Heart Failure

Patients with advanced cancer often present with a clinical phenotype that strikingly resembles chronic heart failure. This condition, sometimes referred to as ‘cardiac wasting,’ involves symptoms such as dyspnea, congestion, and significant physical dysfunction. The pathophysiological link between malignancy and cardiac impairment is multifaceted, involving systemic inflammation, the cardiotoxic effects of chemotherapy, and metabolic derangements. Despite these similarities, the efficacy of standard heart failure therapies—which have revolutionized outcomes in traditional cardiology—remains poorly understood in the context of specialized palliative care for terminal cancer.

The EMPATICC trial (Heart failure therapy in patients with advanced cancer receiving specialized palliative care) was designed to address this unmet need. It specifically targeted patients with stage 4 solid tumors who were receiving specialized palliative care and had a limited life expectancy. The goal was to determine if a multi-drug heart failure regimen could improve a patient’s ability to maintain self-care and functional independence during their remaining time.

Study Design and Methodology

The EMPATICC trial was a double-blind, randomized, placebo-controlled trial conducted across five centers. It enrolled 93 patients with stage 4 solid tumors and a life expectancy estimated between 1 and 6 months. To be included, patients had to meet at least two cardiovascular risk criteria (such as elevated biomarkers or history of hypertension) and at least one criterion for functional limitation.

Participants were randomized 1:1 to receive either an optimized, four-drug heart failure regimen or a matching placebo. The intervention included:

• Sacubitril/valsartan (an ARNI)
• Empagliflozin (an SGLT2 inhibitor)
• Ivabradine (an If channel blocker)
• Ferric carboxymaltose (intravenous iron)

The primary endpoint was hierarchical and analyzed using a win ratio approach. It included (i) days alive and able to wash oneself, (ii) the ability to walk 4 meters, and (iii) the self-reported Patient Global Assessment (PGA) of subjective well-being during a 30-day placebo-controlled phase.

Key Findings: A Complex Picture of Palliative Intervention

The trial’s primary endpoint did not show a statistically significant difference between the heart failure therapy group and the placebo group. The win ratio was 0.95 (95% CI 0.57-1.58; P = .83), indicating that the intervention did not improve the combined measure of survival and self-care ability in this specific cohort.

A major factor in these results was the high mortality rate inherent to the study population. At the 30-day mark, 32% of all randomized patients had passed away, with no significant difference in mortality between the two groups. This high early mortality suggests that for many patients in the terminal stages of cancer, the disease progression may be too advanced for cardiovascular optimization to translate into functional gains within a short timeframe.

Secondary Results in the Survivor Cohort

Interestingly, when the researchers analyzed the patients who survived to the 30-day mark, several positive signals emerged. In the treatment group, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels—a hallmark biomarker of cardiac stress—decreased by 41% (P = .040). Furthermore, the left ventricular ejection fraction (LVEF) showed a modest but statistically significant increase of 2.9% (P = .036).

Perhaps most importantly for palliative care, the subjective well-being of survivors improved. The odds ratio for improved PGA scores was 0.22 (95% CI 0.06-0.75; P = .016), suggesting that those who remained stable enough to benefit from the medication felt better than those on placebo.

Expert Commentary: Navigating the Palliative Frontier

The EMPATICC trial highlights the immense challenges of conducting clinical research in a palliative care setting. The ‘negative’ primary result underscores the reality that for patients with a very short life expectancy, aggressive multi-drug heart failure therapy may not be the primary driver of functional independence. However, the secondary findings provide a compelling argument for individualized cardio-oncology care.

Clinicians must weigh the burden of adding four new medications to a palliative regimen against the potential for improved quality of life. The reduction in NT-proBNP and the improvement in PGA scores suggest that some patients experience a genuine reduction in cardiac-related symptom burden. This ‘hypothesis-generating’ data suggests that there may be a subset of advanced cancer patients—perhaps those with a slightly longer life expectancy or more pronounced cardiac dysfunction—who would benefit significantly from HF therapy.

From a biological perspective, the use of SGLT2 inhibitors and ARNIs in this population is intriguing. These drugs have systemic effects beyond the heart, including potential impacts on inflammation and metabolic efficiency, which might contribute to the improved sense of well-being reported by survivors.

Conclusion and Summary

In conclusion, the EMPATICC trial demonstrates that while optimized heart failure therapy does not universally improve self-care ability in a high-mortality palliative cancer population, it does offer physiological and subjective benefits to those who survive the initial month of treatment. These findings emphasize that ‘one size does not fit all’ in cardio-oncology. Future research should focus on identifying biomarkers or clinical profiles that can predict which palliative patients are most likely to derive a quality-of-life benefit from heart failure interventions.

For now, the trial serves as a reminder that even in the final months of life, cardiac health remains a relevant component of holistic patient care, provided the interventions are tailored to the individual’s prognosis and goals of care.

Funding and ClinicalTrials.gov

The study was supported by various academic and clinical grants. Detailed information regarding the trial registration can be found at ClinicalTrials.gov (NCT number often associated with the EMPATICC protocol, though not explicitly provided in the abstract, the citation points to European Heart Journal 2026).

References

Anker MS, Mahabadi AA, Totzeck M, et al. Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). European Heart Journal. 2026-Mar-05;47(9):1034-1046. PMID: 40884070.